Skip to main content

A young woman selecting medicine from a pharmacy

Scientific Posters

Explore bioMérieux's collection of scientific posters showcasing research and insights in Pharmaceutical Quality Control.

TBN-ISCT-3P

Digitalization and Automation of the Environmental Monitoring Process in C&GT Manufacturing GMP Facilities: Solution to Leverage QC Operational Efficiency, Compliance and Optimize Resources Allocation

Microbial Environmental Monitoring (EM) is crucial to assure patient safety. The visual end point reading of petri dishes has been used for decades without a true performance assessment. Besides, there is growing interest in EM automation technologies.

Optimizing Automated Growth-Based Methods for Faster Sterility Release Testing of Cell & Gene Therapy Products

Optimizing Automated Growth-Based Methods for Faster Sterility Release Testing of Cell & Gene Therapy Products

Automated Growth-based methods are used for rapid detection of microbial contamination in pharmaceutical products such as Cell and gene therapy (CGT). For therapies on the critical path to patient treatment, every day/hour gained on release testing is crucial to accelerate delivery to patients in need.

TBN-ISCT-BIOFIRE

Automated Nucleic Acid Amplification Assay for Mycoplasma Detection in Cell and Gene Therapy Products

Cell and gene therapies (C&GT) or Advanced Therapeutic Medicinal Products (ATMP) are innovative medicine developed to treat cancers, rare diseases, autoimmune disorders, and injuries. As these therapies utilize living cells, they produce a product with a short shelf life. While microbiological examination of cell-based products is critical to ensure patient safety, challenges exist to enable testing and obtaining rapid results prior to patient infusion.

Performance study BACT/ALERT® 3D growth promotion antimicrobial neutralization

BACT/ALERT® 3D is an effective, safe and proven solution for industrial sterility testing.

Mycoplasma Release Testing Cell and Gene Therapy Product Samples

Testing for mycoplasma contamination is a required release test for Cell & Gene Therapy (CGT) products as specified in the major pharmacopeias(1-3).

Recombinant Factor C Characterization Studies Confirm the Published Structure and Function of Manufactured rFC

With the advent of first the EU Pharmacopeial Chapter 2.6.32 (2020) and now the publication of USP Chapter <86> (2024) on the use of recombinant Factor C assays, the manufactured products supplied must meet customer confidence expectations in terms of r-Protein characterization. Both current and historical QC characterization tests are described here for ENDOZYME II. The known and therefore expected structure of the complex molecule is shown below from: Shibata et al. 2018 “Intermolecular autocatalytic activation of serine protease zymogen factor C through an active transition state responding to lipopolysaccharide” (1).

Performance validation environmental monitoring automation

Environmental Monitoring (EM) is crucial to assure patient safety. The visual end point reading of petri dishes has been used for decades without a true performance assessment. Automatization technologies are more present and improve EM practices.

Mycoplasma release test with low volume protocol: From sample to results in less than 1 hour

Improved Time-To-Detection of Slow Growers Microorganisms with an Automated Growth Based Method

Presenting data to showcase how optimization of BACT/ALERT® 3D DUAL-T incubation conditions can lead to notable improvements in time-to-detection.

Testing Cell Therapy and Bioproduction Samples

Various pharmacopoeias, including the USP, specify a test for mycoplasma contamination must be performed as part of the release testing of a product manufactured in the presence of eukaryotic cells (1).

Testing Bioproduction Samples

This poster presents results from independent studies performed by 4 bioproduction companies using the BIOFIRE® Mycoplasma system that can detect >130 species of mycoplasma. The BIOFIRE® filmarray system condenses all the steps of a conventional PCR test into an enclosed pouch and provides sample to answer in less than one hour with as little as 2 minutes of hands-on time.

Mycoplasma release test with low volume protocol: From sample to results in less than 1 hour

Rapid Robust Mycoplasma Detection System for Release Testing of Cell and Gene Therapy Products Containing Mammalian Cells in 1-Hour

Introduce C&GT product specific protocols that allows the inclusion of mammalian cells thus aligning with the upcoming EP guideline (4) whilst providing the required level of detection (≤ 10 CFU/mL) as a Mycoplasma release test.

Mycoplasma release test with low volume protocol: From sample to results in less than 1 hour

Mycoplasma release test with low volume protocol: From sample to results in less than 1 hour

Presenting a new Low Volume protocol that allows the inclusion of mammalian cells from high cell density products thus aligning with the upcoming EP guideline whilst providing the required level of detection (≤ 10 CFU/mL) as a mycoplasma release test.

Ultra-Rapid Microbial Detection in Cell and Gene Therapy Products

Ultra Rapid Microbial Detection in Cell and Gene Therapy Products

In this study, the Most Probable Number (MPN) was used to demonstrate that the LoD of the SCANRDI® CELL-BURST is not significantly different from the LoD of a traditional plate counting method on 10 compendial strains. To show the equivalency, the proportion of positive results was compared between both methods for all strains and all dilutions with a non-inferiority test of Farrington-Manning, with a 20% margin.

Automated Flow Cytometry Assay Facilitates Monitoring of T Cell Health for Cell Therapy Manufacturing

The ACCELLIX™ platform enables automated, standardized characterization of cell materials at the point of need, minimizing variability and subjective data analysis, and providing rapid cell phenotyping for cell therapy development and manufacturing.

Evaluating the Automated ACCELLIX™ Platform Against Conventional Flow Cytometry for Cell Therapy Samples

The ACCELLIX™ Platform demonstrated strong concordance with conventional flow cytometry across multiple PBMC lots and treatment conditions, enabling successful analysis of starting materials, in-process samples and final drug products. The platform’s FCS export capability allowed for manual review and verification when required.

Hematopoietic Stem/Progenitor Cell Enumeration in Apheresis Collections Using a New Microfluidic Cartridge-Based Flow Cytometry Platform

Preliminary results indicate feasibility and accuracy of the ACCELLIX™ method for dual CD34+/CD3+ phenotyping and enumeration in a single assay.

ACCELLIX™ Reproducible QC Poster

Automating Flow Cytometry for Objective & Reproducible Cell Therapy Quality Control

The ACCELLIX™ platform has the potential to improve cell therapy QC efficiency by providing a simple and rapid workflow that minimizes process variability and subjective data analysis.

Automated Flow Cytometry Enables Standardized, Rapid Profiling of Cellular Starting Material for Predictable, Potent Products

The ACCELLIX™ automated flow cytometry platform harmonizes results across operators and sites, providing a meaningful step forward in standardization of flow cytometry and linking starting material assessment with predictable, potent cell therapy products.

The ACCELLIX™ Automated Flow Cytometer

To demonstrate reproducibility and efficiency, Accellix, in collaboration with Triumvira, conducted a study that aims to demonstrate the ease of use, high reproducibility and comparability of the ACCELLIX™ platform to conventional cytometers and cell counters.

Automated, Rapid, Point-of-Collection Flow Cytometry for Leukapheresis-Derived Starting Materials

The ACCELLIX™ platform enables automated, standardized characterization of leukapheresis-derived starting material at the point of collection, minimizing process variability and subjective data analysis, and providing rapid leukopak phenotyping for cell therapy development and manufacturing.

Implementing Dynamic Automated Flow Cytometric Analysis for Rapid Cell Therapy Manufacturing QC

ACCELLIX™ offers assay-specific autoclassification software that can be tailored to meet requirements for different cell therapy products and workflows, generating automated results at the end of each run for real-time evaluation.

From Bench to Reality: the Role of Natural Contaminations in LER Investigations

There is ongoing debate regarding the most appropriate type of endotoxin to use in Low Endotoxin Recovery (LER) Hold Time Studies. PDA Technical Report 82 (TR82) recommends Reference Standard Endotoxin (RSE) and Control Standard Endotoxin (CSE) as the primary choices.

Comparing Safety Margin Methods for USP <72> Compliance

Automated growth-based methods are often used for rapid microbial contamination detection in short shelf-life pharmaceutical products such as Cell and Gene Therapies (CGT). For such products, every hour gained on release testing is vital to patients in need.

Quality Control of BACT/ALERT® Culture Media

A study was conducted using commercially prepared organisms evaluating both a comprehensive organism panel as well as a streamlined method utilizing only two organisms from the panel.

From Parametric Rules to Artificial Intelligence: A New Era in Microbial Image Analysis

Machine learning, particularly deep learning, offers a powerful alternative by learning complex patterns from large datasets, enabling more accurate and adaptable classification.